Company intelligence
Merakris Therapeutics, Inc.
A leader in developing regenerative products within the aesthetic, wound care, and ophthalmology markets.
About Merakris Therapeutics, Inc.
A pioneer in biotechnology, Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative healthcare products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies. Merakris Therapeutics strives to: • Be a leader in the research and development of regenerative medicine. • Deliver effective medical therapies that require fewer treatments and help to improve patient outcomes, while reducing the overall cost of care. • Educate patients and healthcare providers about the benefits of alternative therapies and regenerative medicine in comparison to standard or more invasive treatment options.
Verified activity
Signals from Merakris Therapeutics, Inc.
5 published signals
Products & Services
Merakris Therapeutics, Inc. launched AmnioSurge™ ASG, a lyophilized amnion/chorion ring designed to integrate with circular stapling techniques for colorectal procedures.
Reported by Merakris Therapeutics, Inc.
Products & Services
Merakris Therapeutics, Inc. introduced AmnioSurge™ Amniotic Anastomosis Support Graft (ASG), a novel ring-configured amniotic membrane allograft designed for colorectal and internal anastomotic procedures.
Reported by Merakris Therapeutics, Inc.
Partnerships
Merakris Therapeutics, Inc. expanded access to AmnioSurge™ through a strategic distribution partnership with 360 Medical across the United States.
Reported by Merakris Therapeutics, Inc.
Products & Services
Merakris Therapeutics, Inc. launched AmnioSurge™ ASG, a lyophilized amnion/chorion ring designed to integrate with circular stapling techniques.
Reported by Chris Broderick
Research & Knowledge
Merakris Therapeutics, Inc. continues to focus on developing MTX-001 as a next-generation biological drug designed to address the underlying biology of stalled healing.
Reported by Chris Broderick